Senseonics, the company behind the Eversense 365 implantable continuous glucose monitoring (CGM) system, has received CE mark approval. The approval clears the way for the device to launch in several European markets, with Senseonics planning an initial rollout in Germany, Italy, Spain, and Sweden in the coming months.

Eversense 365 is a fully implantable continuous glucose monitoring system designed to deliver real-time glucose readings for up to one year from a single sensor. The tiny sensor is implanted under the skin of the arm through a short procedure and requires a transmitter above the skin to monitor glucose readings.

Eversense 365 is just the beginning of what Senseonics has in store for its implantable. The company recently supported a limited rollout of users pairing Eversense with the twiist insulin pump, hinting at deeper integration with automated insulin delivery systems. Senseonics is also developing future initiatives such as Eversense Gemini and Freedom, which aim to eliminate the need for an external transmitter and allow users to retrieve glucose data by scanning with their smartphone.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.